Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

74
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
74
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

91
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
91
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

201
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
201
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

165
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
165
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

83
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
83
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

104
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
104

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrasound-assisted catheter-directed thrombolysis for pulmonary embolism: current evidence, limitations, and future directions.

Future cardiology·2026
Same author

Characteristics of Coronary Intra- or Extramedial Hematomas Causing Emergent Return to Catheterization Laboratory After Percutaneous Coronary Intervention.

JACC. Cardiovascular interventions·2026
Same author

Outcome of Patients Presenting With High-Risk Pulmonary Embolism Treated With Mechanical Thrombectomy: A Subgroup Analysis From the STRIKE-PE Study.

Journal of the Society for Cardiovascular Angiography & Interventions·2026
Same author

Long-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia: 3-Year Results From the LIFE-BTK Trial.

Journal of the American College of Cardiology·2026
Same author

Pharmacokinetic Profile of Everolimus Eluted From the Esprit BTK Scaffold: A LIFE-BTK Pharmacokinetics Substudy.

Journal of the Society for Cardiovascular Angiography & Interventions·2026
Same author

Endovascular Drug Delivery from Stents and Balloons in Peripheral Arteries: What Every Interventionalist Must Know.

Interventional cardiology clinics·2026

Related Experiment Video

Updated: Mar 20, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

12.8K

Next-Generation Drug Delivery Systems and Drugs for Vascular Intervention.

Logan D Cho1, Sahil A Parikh2

  • 1Department of Medicine, Columbia University Irving Medical Center, 622 W 168th Street #205, New York, NY 10032, USA.

Interventional Cardiology Clinics
|March 18, 2026
PubMed
Summary

Modern revascularization uses drug-eluting stents and balloons to treat coronary and peripheral artery disease. Ongoing research focuses on advanced drug delivery systems to overcome challenges like restenosis and thrombosis.

Keywords:
Bioresorbable scaffoldDrug deliveryPaclitaxelSirolimus

More Related Videos

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases
04:59

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases

Published on: June 20, 2025

921
Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

11.6K

Related Experiment Videos

Last Updated: Mar 20, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

12.8K
Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases
04:59

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases

Published on: June 20, 2025

921
Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

11.6K

Area of Science:

  • Cardiovascular medicine
  • Biomaterials science
  • Nanotechnology

Background:

  • Endovascular revascularization has evolved from simple balloon angioplasty and bare metal stents.
  • Current methods employ drug-eluting stents and balloons with antiproliferative drugs and nanotechnology.
  • Neointimal hyperplasia remains a significant issue, leading to stent thrombosis and in-stent restenosis.

Purpose of the Study:

  • To review current therapeutic approaches in endovascular revascularization.
  • To summarize advancements in drug delivery systems, including nanotechnology.
  • To highlight emerging technologies for next-generation anti-restenosis treatments.

Main Methods:

  • Literature review of contemporary endovascular revascularization techniques.
  • Analysis of drug delivery platforms utilizing nanotechnology.
  • Exploration of ongoing research in anti-restenosis agents and technologies.

Main Results:

  • Drug-eluting technologies have improved revascularization outcomes but challenges persist.
  • Nanotechnology plays a crucial role in modern drug delivery for vascular applications.
  • Neointimal hyperplasia, stent thrombosis, and in-stent restenosis are key areas for improvement.

Conclusions:

  • Despite advancements, neointimal hyperplasia remains a clinical challenge in endovascular revascularization.
  • Next-generation therapeutics and drug delivery platforms are under development to improve long-term outcomes.
  • Continued innovation in nanotechnology and anti-restenosis agents is essential for future progress.